Pattern of Immunophenotypic Aberrant Expression in De-Novo Acute Leukaemia
Abstract
Background: Aberrant expression (AE) of Acute Leukaemia (AL) is essential to confirm the diagnosis of AL patients whether it is biphenotypic/mix phenotypic AL or it is AL with AE. Objectives: This study is conducted to observe the diversity of aberrant immunophenotypic expressions among the patients of acute leukaemia with varying frequencies, to find out the correlation between aberrantly expressed immunophenotypic markers with different variety of French American British (FAB) sub classification of acute leukaemia and any correlation of clinical presentation of AL patients with aberrantly expressed immunophenotypic markers. Methodology: This cross-sectional observational study was carried out in the department of Haematology, BSMMU, Bangladesh on 50 patients from 14 to 65 years of age of both sex of newly diagnosed de- novo untreated AL patients from January 2017 to June 2018. Informed written consent & clinical history is taken and physical examinations were done in a predesigned data collection sheet. Then Bone marrow (BM) with peripheral blood sample for morphology and immunophenotyping were done in the laboratory of the Haematology department of BSMMU. After collection of data, these data were analysed for the final result. Result: In this study, 24 (48%) patients of de-novo Acute Leukaemia have Immunophenotypic aberrant expressions. Among them 12 (24%) patients were AML with AE, 9 (18%) patients were B ALL with AE, 3 (6%) patients were T ALL with AE and 2 (4%) patients were MPAL. In case of AML the most frequent Lymphoid aberrant marker is CD7 (12%), In B ALL the most frequent aberrant marker is CD5 (10%) and in T ALL the most frequent aberrant marker is CD10 (4%). Conclusion: In de-novo acute leukaemia, there is significant number of patients have aberrant expression which should be differentiated from biphenotypic/mix phenotypic AL for therapeutic and prognostic implications.
Full text article
References
Kawthalkar SM; Essentials of Haematology, Acute Leukaemia, Diagnosis and Classification, 2nd edition, 2013, Chapter 5, Page: 236.
Lewis RE, Cruse JM, Sanders CM, Webb RN, Suggs JL. Aberrant expression of T-cell markers in acute myeloid leukemia. Exp Mol Pathol. 2007; Dec;83(3):462-3. Epub 2007 Sep 7.
Tong H, Wang Q, Lu C, Liu Z, Hu Y. Immunophenotypic, cytogenetic, and clinical features of 207 cases of childhood acute lymphoblastic leukemia in china. J Pediatr Hematol Oncol. 2011 Aug;33(6):437-41.
Venkateswaran S P, Jojo A, Vidhyadharan G, Unni M et al. A Clinicopathological Correlation of Acute Leukaemias in relation to Immunophenotyping and Cytogenetics. International Journal of Collaborative Research on Internal Medicine and Public Health. 2012; 4(10): 1713–1737.
El-Sissy AH, El-Mashari MA, Bassuni WY, El-Swaayed AF. Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia. J Egypt Natl Cancer Inst. 2006;18(3):244– 249.
Khalidi HS, Chang KL, Medeiros LJ, Brynes RK, Slovak ML, MurataCollins JL and Arber DA. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol. 1999; 111:467-76.
Khalidi HS, Medeiros LJ, Chang KL, Brynes RK, Slovak ML and Arber DA. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol. 1998; 109:211-20.
Cruse JM, Lewis RE, Pierce S, Lam J and Tadros Y. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol. 2005; 79:39-41.
Saxena A, Sheridan DP, Card RT, McPeek AM, Mewdell CC and Skinnider LF. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol. 1998; 58:278-84.
Frater JL, Yaseen NR, Peterson LC, Tallman MS and Goolsby CL. Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage. Arch Pathol Lab Med. 2003; 127:356-9.
Reading CL, Estey EH, Huh YO et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood. 1993;81(11):3083–3090.
Bahia DM, Yamamoto M, Chauffaille Mde L et al. Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical signi?cance. Haematologica. 2001; 86(8): 801–806.
Vitale A, Guarini A, Ariola C et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica. 2007;92(3):342–348.
Abbasi N, Kamal N, AL-Kaisi N, Aljaafreh L. Immunophenotypic Profile of Acute Leukemia Cases Using Multicolor Flow Cytometry; Three Year Experience at King Hussein Medical Center. JOURNAL OF THE ROYAL MEDICAL SERVICES. 2015; 22(3): 53–58.
Jha R, Grover G, Bose P Lymphoid associated antigen expression in new cases of Acute Myeloid Leukemia; Journal of Pathology of Nepal. 2013; 3:487-490.
Jahedi M, Shamsasenjan K, Sanaat Z et al. Aberrant Phenotype in Iranian Patients with Acute Myeloid Leukemia; Advanced Pharmaceutical Bulletin.2014;4(1):43-47.
Gupta A., Pal A. and Nelson S. Immunophenotyping in Acute Leukemia?: A clinical study; International Journal of Scientific Study. 2015; 3(5): 129–136.
Legrand O, Perrot JY, Simonin G, Baudard M, Cadiou M, Blanc C, et al. Adult biphenotypic acute leukaemia: An entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein overexpression. Br J Haematol. 1998, 100: 147-55.
Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995, 9 (10): 1783-6.
Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Acute myeloid leukemias. Chapter 4. In: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon; IARC Press. 2001, pp. 75-107.
Kozlov I, Beason K, Yu C, Hugh M. CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity. Cancer Genet Cytogenet. 2005, 163 (1): 62-7.
Authors
Copyright (c) 2022 Kazi Mohammad Kamrul Islam, Israt Jahan, Md Adnan Hasan Masud, Md. Golzar Hossain, Nishat Mahzabin, Md. Arif-Ur- Rahman, Munim Ahmed, Mujahida Rahman, Md. Salahuddin Shah, Md. Abdul Aziz, Masuda Begum, A B M Yunus
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article published under the Creative Commons Attribution 4.0 International License, which permits its free use, distribution, and reproduction in any medium or format, even used for commercial purposes, provided the original work is properly cited.